{"protocolSection": {"identificationModule": {"nctId": "NCT01720069", "orgStudyIdInfo": {"id": "VR506/2/004"}, "organization": {"fullName": "Vectura Limited", "class": "INDUSTRY"}, "briefTitle": "Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma", "officialTitle": "A Randomised Double-blind, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of VR506 From a New Dry Powder Inhaler in Subjects With Severe Persistent Asthma Requiring Oral Corticosteroid Therapy."}, "statusModule": {"statusVerifiedDate": "2020-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-10"}, "primaryCompletionDateStruct": {"date": "2013-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-10-30", "studyFirstSubmitQcDate": "2012-10-30", "studyFirstPostDateStruct": {"date": "2012-11-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-03-19", "resultsFirstSubmitQcDate": "2020-04-09", "resultsFirstPostDateStruct": {"date": "2020-04-21", "type": "ACTUAL"}, "dispFirstSubmitDate": "2014-09-11", "dispFirstSubmitQcDate": "2014-09-11", "dispFirstPostDateStruct": {"date": "2014-09-22", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2020-04-09", "lastUpdatePostDateStruct": {"date": "2020-04-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Vectura Limited", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "To evaluate the clinical efficacy, safety, tolerability and dose-response relationship, using oral corticosteroid (OCS) modulation, of 3 different doses of VR506 using a twice daily regimen from a new dry powder inhaler (nDPI) for 16 weeks in subjects with severe persistent asthma requiring OCS therapy, i.e. Step 5 treatment as defined by modified Global Initiative for Asthma (GINA) guidelines 2011."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 197, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dose 1 VR506", "type": "ACTIVE_COMPARATOR", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device", "interventionNames": ["Drug: VR506"]}, {"label": "Dose 2 VR506", "type": "ACTIVE_COMPARATOR", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device", "interventionNames": ["Drug: VR506"]}, {"label": "Dose 3 VR506", "type": "ACTIVE_COMPARATOR", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device", "interventionNames": ["Drug: VR506"]}], "interventions": [{"type": "DRUG", "name": "VR506", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device", "armGroupLabels": ["Dose 1 VR506", "Dose 2 VR506", "Dose 3 VR506"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Prednisone/Prednisolone Dose for Analysis (PDA) at End of Study (Week 16)", "description": "The mean asthma control prednisone/prednisolone dose at end of study (week 16)", "timeFrame": "16 weeks"}], "secondaryOutcomes": [{"measure": "Mean Change From Start of Treatment Baseline to End of Study (Week 16) for In-clinic Morning Pre-Dose Forced Expiratory Volume In 1 Second (FEV1)", "timeFrame": "Baseline and 16 weeks"}, {"measure": "Mean Change From Start of Treatment Baseline to End of Study (Week 16) for Asthma Control Questionnaire (ACQ-5) Mean Total Score", "description": "Change from baseline to end of study (week 16) in 5 item asthma control questionnaire (ACQ-5) mean total score (range 0 (better) to 6 (worse)). The mean total score is calculated as the mean for each subject at each visit of 5 questions, each scored from 0 (better) to 6 (worse).", "timeFrame": "Baseline and 16 weeks"}, {"measure": "Mean Change From Start of Treatment Baseline to End of Study (Week 16) for In-clinic Weekly Morning Pre-dose Peak Expiratory Flow (PEF)", "timeFrame": "Baseline and 16 weeks"}, {"measure": "Mean Change From Start of Treatment Baseline to End of Study (Week 16) for Weekly Average Asthma Night-time Symptom Score", "description": "To measure the change from baseline to end of study for the weekly mean asthma night time symptom score, scored from 0 (not at all bothered) to 6 (severely bothered).", "timeFrame": "Baseline and 16 weeks"}, {"measure": "Number of Participants With Withdrawals Due to Worsening of Asthma", "timeFrame": "16 weeks"}, {"measure": "Assessment of Acceptability of the Device", "description": "Percentage of subjects that overall found it very easy or fairly easy to use the inhaler, based on inhaler acceptability questionnaire", "timeFrame": "16 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion:\n\n* Written informed consent\n* Adolescents aged 12-17 years \\& adults aged 18-65 years (both inclusive)\n* Documented clinical history of severe asthma requiring prednisone/prednisolone therapy, high-intensity treatment ICS, OCS, LABA\n* Stable OCS dose for \u22657 days before Screening Visit \\& during Screening Period.\n* At least 80% compliant w/regular asthma medication per investigator at end of Screening Period\n* Documented asthma reversibility within 5 yrs prior to/during Screening Period, or diagnosis of asthma that is incontrovertible per investigator\n* Ability to use nDPI correctly, per investigator's review of completed inhaler operation checklist\n* Ability to use eDiary correctly, assessed by investigator at end of Screening Period\n* Ability to comply w/study procedures, including blood sampling\n* Ability to perform technically satisfactory pulmonary function tests\n* Available to complete all study visits before 12 noon\n* BMI of 16-26 kg/m2 in adolescents and 18-32 kg/m2 in adults\n* Oral PIF \u226540 L/min, using an appropriate device set to match resistance of inhaler\n* Good health, except for presence of asthma, per medical history/physical examination\n* Negative drug/alcohol/urine cotinine screen. Subjects must test negative for amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, cotinine, ethanol \\& opiates (unless given as prescription medicine)\n* Non-smokers or ex-smokers with a smoking history of less than 10 pack-yrs (e.g. \\<20 cigarettes per day for 10 years or \\<40 cigarettes per day for 5 years) \\& stopped smoking for at least 1 year prior to Screening Visit. Smoking will not be permitted throughout study\n* Female subjects of child-bearing potential must be using medically acceptable forms of contraception \\[abstinence, hormonal (oral/implant/transdermal/injection), in use for \u22653 consecutive months before first dose of study medication, double barrier (condom w/spermicide, or diaphragm w/spermicide), IUD, or vasectomised partner (\u22656 months since vasectomy)\\].\n\nExclusion:\n\n* Regular use (\u22653 times/wk) of topical steroids to treat dermatitis/rhinitis/allergic conjunctivitis, within 28 days of Screening Visit\n* Subjects who have/who have had, an upper/lower respiratory tract infection within 28 days of Screening Visit\n* Subjects w/\"brittle asthma\n* Subjects w/asthma that required admission to an ICU and/or ventilation within previous 12 months\n* Subjects whose comorbidities, per investigator's opinion, are major contributors to their respiratory symptoms (e.g. COPD, bronchiectasis, dysfunctional breathlessness, vocal cord dysfunction, gastro-oesophageal reflux)\n* Previously/currently diagnosed as having Churg-Strauss syndrome\n* Previously/currently diagnosed as having pulmonary eosinophilia\n* History of lung cancer\n* Subjects w/current diagnosis of HIV infection\n* Active chronic hepatitis B or C infection\n* Subjects who have clinically significant abnormality/finding from examination, tests, or history that may compromise subject safety, specifically any history of cardiac, renal or hepatic impairment\n* Subjects with an abnormal ECG\n* Persistent arterial hypotension, with average SBP readings of \u226495 mmHg\n* Persistent elevation of blood pressure, with average SBP readings of \u2265160 mmHg or average DBP readings of \u2265100 mmHg\n* Pregnant or lactating females\n* Participation in another clinical study in 28 days prior to Screening Visit\n* Evidence of clinically significant renal, hepatic, cardiac, pulmonary (apart from asthma) or metabolic dysfunction, e.g. diabetes mellitus, thyrotoxicosis, uncorrectable hypokalaemia, or predisposition to low levels of serum potassium\n* Current/history of drug/alcohol abuse/dependence per WHO criteria\n* Inability to communicate well w/investigator\n* Donation of \u2265450 mL of blood/blood products within previous 3 months prior to screening\n* History of allergy/intolerance/contraindications to corticosteroids/lactose, or severe allergy to milk proteins\n* Consumption of alcohol- or caffeine-containing foods/beverages from midnight before or during Screening Visit\n* History of medically diagnosed chronic respiratory diseases other than asthma (e.g. chronic obstructive pulmonary disease, ABPA in the absence of asthma)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "65 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Vectura Clinical Trial Site 01001", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Vectura Clinial Trial Site 01005", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Vectura Clinical Trial Site 01006", "city": "Celebration", "state": "Florida", "zip": "34747", "country": "United States", "geoPoint": {"lat": 28.32529, "lon": -81.53313}}, {"facility": "Vectura Clinical Trial Site 01015", "city": "Hialeah", "state": "Florida", "zip": "33018", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"facility": "Vectura Clinical Trial Site 01012", "city": "Miami Lakes", "state": "Florida", "zip": "33016", "country": "United States", "geoPoint": {"lat": 25.90871, "lon": -80.30866}}, {"facility": "Vectura Clinical Trial Site 01014", "city": "Orlando", "state": "Florida", "zip": "32806", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Vectura Clinical Trial Site 01003", "city": "Tampa", "state": "Florida", "zip": "33613", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Vectura Clinical Trial Site 01011", "city": "Saint Louis", "state": "Missouri", "zip": "63110-1093", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Vectura Clinical Trial Site 01013", "city": "Jersey City", "state": "New Jersey", "zip": "07306", "country": "United States", "geoPoint": {"lat": 40.72816, "lon": -74.07764}}, {"facility": "Vectura Clinical Trial Site 01004", "city": "Bronx", "state": "New York", "zip": "10461", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Vectura Clinical Trial Site 01007", "city": "El Paso", "state": "Texas", "zip": "79925", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Vectura Clinical Trial Site 08006", "city": "Ruse", "zip": "7000", "country": "Bulgaria", "geoPoint": {"lat": 43.85639, "lon": 25.97083}}, {"facility": "Vectura Clinical Trial Site 08005", "city": "Sofia", "zip": "1000", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Vectura Clinical Trial Site 08001", "city": "Sofia", "zip": "1431", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Vectura Clinical Trial Site 08003", "city": "Sofia", "zip": "1431", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Vectura Clinical Trial Site 08007", "city": "Sofia", "zip": "1431", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Vectura Clinical Trial Site 08004", "city": "Sofia", "zip": "1606", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Vectura Clinical Trial Site 08002", "city": "Stara Zagora", "zip": "6000", "country": "Bulgaria", "geoPoint": {"lat": 42.43278, "lon": 25.64194}}, {"facility": "Vectura Clinical Trial Site 08008", "city": "Varna", "zip": "9000", "country": "Bulgaria", "geoPoint": {"lat": 43.21667, "lon": 27.91667}}, {"facility": "Vectura Clinical Trial Site 03006", "city": "Berlin", "zip": "10717", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Vectura Clinical Trial Site 03009", "city": "Berlin", "zip": "12203", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Vectura Clinical Trial Site 03004", "city": "Bonn", "zip": "53119", "country": "Germany", "geoPoint": {"lat": 50.73438, "lon": 7.09549}}, {"facility": "Vectura Clinical Trial Site 03008", "city": "Donaustauf", "zip": "93093", "country": "Germany", "geoPoint": {"lat": 49.03258, "lon": 12.20459}}, {"facility": "Vectura Clinical Trial Site 03003", "city": "Dortmund", "zip": "44263", "country": "Germany", "geoPoint": {"lat": 51.51494, "lon": 7.466}}, {"facility": "Vectura Clinical Trial Site 03007", "city": "Geesthacht", "zip": "21502", "country": "Germany", "geoPoint": {"lat": 53.43575, "lon": 10.3779}}, {"facility": "Vectura Clinical Trial Site 03001", "city": "Hamburg", "zip": "22767", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Vectura Clinical Trial Site 03005", "city": "Heidelberg", "zip": "69126", "country": "Germany", "geoPoint": {"lat": 49.40768, "lon": 8.69079}}, {"facility": "Vectura Clinical Trial Site 03002", "city": "Rudersdorf", "zip": "15562", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "Vectura Clinical Trial Site 04001", "city": "Budapest", "zip": "1121", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Vectura Clinical Trial Site 04004", "city": "Budapest", "zip": "1125", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Vectura Clinical Trial Site 04003", "city": "Debrecen", "zip": "4032", "country": "Hungary", "geoPoint": {"lat": 47.53333, "lon": 21.63333}}, {"facility": "Vectura Clinical Trial Site 04002", "city": "Rakoczi", "zip": "125 127", "country": "Hungary"}, {"facility": "Vectura Clinical Trial Site 04005", "city": "Rakoczi", "zip": "7100", "country": "Hungary"}, {"facility": "Vectura Clinical Trial Site 05008", "city": "Bialystok", "zip": "15-003", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Vectura Clinical Trial Site 05002", "city": "Bialystok", "zip": "15-276", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Vectura Clinical Trial Site 05010", "city": "Bialystok", "zip": "15-430", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Vectura Clinical Trial Site 05011", "city": "Krakow", "zip": "31-024", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Vectura Clinical Trial Site 05001", "city": "Lodz", "zip": "90-153", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Vectura Clinical Trial Site 05006", "city": "Lodz", "zip": "90-153", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Vectura Clinical Trial Site 05005", "city": "Lublin", "zip": "20-552", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "Vectura Clinical Trial Site 05007", "city": "Tarnow", "zip": "33-100", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "Vectura Clinical Trial Site 05003", "city": "Warszawa", "zip": "02-097", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Vectura Clinical Trial Site 05009", "city": "Wroclaw", "zip": "51-162", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Vectura Clinical Trial Site 05004", "city": "Zawadzkie", "zip": "47-120", "country": "Poland", "geoPoint": {"lat": 50.60503, "lon": 18.48467}}, {"facility": "Vectura Clinical Trial Site 07001", "city": "Brasov", "zip": "500086", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Vectura Clinical Trial Site 07008", "city": "Bucuresti", "zip": "010457", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Vectura Clinical Trial Site 07005", "city": "Bucuresti", "zip": "020671", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Vectura Clinical Trial Site 07013", "city": "Bucuresti", "zip": "030303", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Vectura Clinical Trial Site 07003", "city": "Bucuresti", "zip": "050554", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Vectura Clinical Trial Site 07006", "city": "Cluj-Napoca", "zip": "400371", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Vectura Clinical Trial Site 07007", "city": "Cluj-Napoca", "zip": "400371", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Vectura Clinical Trial Site 07009", "city": "Cluj-Napoca", "zip": "400371", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Vectura Clinical Trial Site 07010", "city": "Cod", "zip": "700115", "country": "Romania"}, {"facility": "Vectura Clinical Trial Site 07014", "city": "Craiova", "zip": "200515", "country": "Romania", "geoPoint": {"lat": 44.31667, "lon": 23.8}}, {"facility": "Vectura Clinical Trial Site 07002", "city": "Iasi", "zip": "700376", "country": "Romania", "geoPoint": {"lat": 47.16667, "lon": 27.6}}, {"facility": "Vectura Clinical Trial Site 07004", "city": "Marghita", "zip": "415300", "country": "Romania", "geoPoint": {"lat": 47.35, "lon": 22.33333}}, {"facility": "Vectura Clinical Trial Site 07012", "city": "Targu Mures", "zip": "540543", "country": "Romania", "geoPoint": {"lat": 46.54245, "lon": 24.55747}}, {"facility": "Vectura Clinicl Trial Site 07011", "city": "Timis", "zip": "300310", "country": "Romania"}, {"facility": "Vectura Clinical Trial Site 06013", "city": "AR Crimea", "zip": "97403", "country": "Ukraine"}, {"facility": "Vectura Clinical Trial Site 06009", "city": "Donetsk", "zip": "83099", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "Vectura Clinical Trial Site 06012", "city": "Ivano-Frankivsk", "zip": "76018", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Vectura Clinical Trial Site 06010", "city": "Kharkiv", "zip": "61002", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Vectura Clinical Trial Site 06001", "city": "Kharkiv", "zip": "61035", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Vectura Clinical Trial Site 06004", "city": "Kharkiv", "zip": "61106", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Vectura Clinical Trial Site 06006", "city": "Kyiv", "zip": "02232", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Vectura Clinical Trial Site 06002", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Vectura Clinical Trial Site 06015", "city": "Kyiv", "zip": "3680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Vectura Clinical Trial Site 06003", "city": "Kyviv", "zip": "04050", "country": "Ukraine"}, {"facility": "Vectura Clinical Trial Site 06008", "city": "Mykolaiv", "zip": "54003", "country": "Ukraine", "geoPoint": {"lat": 46.96591, "lon": 31.9974}}, {"facility": "Vectura Clinical Trial Site 06011", "city": "Vinnitsa", "zip": "21029", "country": "Ukraine", "geoPoint": {"lat": 49.84639, "lon": 37.71861}}, {"facility": "Vectura Clinical Trial Site 06007", "city": "Zaporizhzhia", "zip": "69600", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"facility": "Vectura Clinical Trial Site 06014", "city": "Zaporizhzhya", "zip": "69118", "country": "Ukraine", "geoPoint": {"lat": 50.60727, "lon": 31.78792}}, {"facility": "Vectura Clinical Trial Site 02003", "city": "Cottingham", "state": "Hull", "zip": "HU16 5JQ", "country": "United Kingdom", "geoPoint": {"lat": 52.50243, "lon": -0.7554}}, {"facility": "Vectura Clinical Trial site 02002", "city": "Birmingham", "zip": "B9 5SS", "country": "United Kingdom", "geoPoint": {"lat": 52.48142, "lon": -1.89983}}, {"facility": "Vectura Clinical Trial Site 02004", "city": "Manchester", "zip": "M23 9LT", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "Vectura Clinical Trial Site 02001", "city": "Newcastle", "zip": "NE7 7DN", "country": "United Kingdom", "geoPoint": {"lat": 54.97328, "lon": -1.61396}}, {"facility": "Vectura Clinical Trial Site 02005", "city": "Nottingham", "zip": "NG5 1PB", "country": "United Kingdom", "geoPoint": {"lat": 52.9536, "lon": -1.15047}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "197 subjects were randomised and 196 received at least one dose of study drug; 1 subject was randomised but not treated.", "groups": [{"id": "FG000", "title": "Dose 1 VR506 50 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "FG001", "title": "Dose 2 VR506 250 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "FG002", "title": "Dose 3 VR506 500 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "62"}, {"groupId": "FG001", "numSubjects": "71"}, {"groupId": "FG002", "numSubjects": "63"}]}, {"type": "Full Anaylsis Set", "achievements": [{"groupId": "FG000", "numSubjects": "62"}, {"groupId": "FG001", "numSubjects": "71"}, {"groupId": "FG002", "numSubjects": "63"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "57"}, {"groupId": "FG001", "numSubjects": "56"}, {"groupId": "FG002", "numSubjects": "48"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "15"}]}], "dropWithdraws": [{"type": "Could not use e-diary correctly", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Randomised without baseline values", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Treatment period withdrawal criteria met", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "OCS bursts occured, discontinued in line", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Non-compliance on using e-diary", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Dose 1 VR506 50 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "BG001", "title": "Dose 2 VR506 250 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "BG002", "title": "Dose 3 VR506 500 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "62"}, {"groupId": "BG001", "value": "71"}, {"groupId": "BG002", "value": "63"}, {"groupId": "BG003", "value": "196"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "62"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "63"}, {"groupId": "BG003", "value": "195"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "42"}, {"groupId": "BG003", "value": "127"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "21"}, {"groupId": "BG003", "value": "69"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Romania", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "49"}]}]}, {"title": "Hungary", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "10"}]}]}, {"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "10"}]}]}, {"title": "Ukraine", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "14"}, {"groupId": "BG003", "value": "47"}]}]}, {"title": "Poland", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "49"}]}]}, {"title": "United Kingdom", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "2"}]}]}, {"title": "Bulgaria", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "19"}]}]}, {"title": "Germany", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "10"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Prednisone/Prednisolone Dose for Analysis (PDA) at End of Study (Week 16)", "description": "The mean asthma control prednisone/prednisolone dose at end of study (week 16)", "populationDescription": "The Full Analysis Set (FAS) was analyzed, however 7 subjects are not included because they had no OCS dose adjustment assessment post-randomisation, and baseline values were not carried forward.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg", "timeFrame": "16 weeks", "groups": [{"id": "OG000", "title": "Dose 1 VR506 50 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "OG001", "title": "Dose 2 VR506 250 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "OG002", "title": "Dose 3 VR506 500 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "70"}, {"groupId": "OG002", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.55", "spread": "6.85"}, {"groupId": "OG001", "value": "4.31", "spread": "7.38"}, {"groupId": "OG002", "value": "3.97", "spread": "6.21"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.772", "statisticalMethod": "ANCOVA"}]}, {"type": "SECONDARY", "title": "Mean Change From Start of Treatment Baseline to End of Study (Week 16) for In-clinic Morning Pre-Dose Forced Expiratory Volume In 1 Second (FEV1)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Baseline and 16 weeks", "groups": [{"id": "OG000", "title": "Dose 1 VR506 50 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "OG001", "title": "Dose 2 VR506 250 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "OG002", "title": "Dose 3 VR506 500 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "71"}, {"groupId": "OG002", "value": "63"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "spread": "0.4"}, {"groupId": "OG001", "value": "0.02", "spread": "0.31"}, {"groupId": "OG002", "value": "0.06", "spread": "0.35"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.891", "statisticalMethod": "ANCOVA"}]}, {"type": "SECONDARY", "title": "Mean Change From Start of Treatment Baseline to End of Study (Week 16) for Asthma Control Questionnaire (ACQ-5) Mean Total Score", "description": "Change from baseline to end of study (week 16) in 5 item asthma control questionnaire (ACQ-5) mean total score (range 0 (better) to 6 (worse)). The mean total score is calculated as the mean for each subject at each visit of 5 questions, each scored from 0 (better) to 6 (worse).", "populationDescription": "Full Analysis Set was analyzed, but number of patients represents subjects with both start of treatment baseline value and end of treatment value where a Last Observation Carried Forward (LOCF) approach was used to impute values of missing post-baseline visits; 1 subject had no post-dose ACQ-5 assessment, baseline value was not carried forward.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and 16 weeks", "groups": [{"id": "OG000", "title": "Dose 1 VR506 50 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "OG001", "title": "Dose 2 VR506 250 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "OG002", "title": "Dose 3 VR506 500 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "70"}, {"groupId": "OG002", "value": "63"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.67", "spread": "0.98"}, {"groupId": "OG001", "value": "-0.77", "spread": "1.15"}, {"groupId": "OG002", "value": "-0.39", "spread": "0.89"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.066", "statisticalMethod": "ANCOVA"}]}, {"type": "SECONDARY", "title": "Mean Change From Start of Treatment Baseline to End of Study (Week 16) for In-clinic Weekly Morning Pre-dose Peak Expiratory Flow (PEF)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "Baseline and 16 weeks", "groups": [{"id": "OG000", "title": "Dose 1 VR506 50 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "OG001", "title": "Dose 2 VR506 250 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "OG002", "title": "Dose 3 VR506 500 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "71"}, {"groupId": "OG002", "value": "63"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2", "spread": "45.7"}, {"groupId": "OG001", "value": "20.1", "spread": "51.7"}, {"groupId": "OG002", "value": "6.1", "spread": "53.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.063", "statisticalMethod": "ANCOVA"}]}, {"type": "SECONDARY", "title": "Mean Change From Start of Treatment Baseline to End of Study (Week 16) for Weekly Average Asthma Night-time Symptom Score", "description": "To measure the change from baseline to end of study for the weekly mean asthma night time symptom score, scored from 0 (not at all bothered) to 6 (severely bothered).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and 16 weeks", "groups": [{"id": "OG000", "title": "Dose 1 VR506 50 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "OG001", "title": "Dose 2 VR506 250 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "OG002", "title": "Dose 3 VR506 500 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "71"}, {"groupId": "OG002", "value": "63"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "1"}, {"groupId": "OG001", "value": "-0.6", "spread": "1"}, {"groupId": "OG002", "value": "-0.2", "spread": "1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.054", "statisticalMethod": "ANCOVA"}]}, {"type": "SECONDARY", "title": "Number of Participants With Withdrawals Due to Worsening of Asthma", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "16 weeks", "groups": [{"id": "OG000", "title": "Dose 1 VR506 50 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "OG001", "title": "Dose 2 VR506 250 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "OG002", "title": "Dose 3 VR506 500 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "71"}, {"groupId": "OG002", "value": "63"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.168", "statisticalMethod": "Fisher Exact"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.363", "statisticalMethod": "Fisher Exact"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.805", "statisticalMethod": "Fisher Exact"}]}, {"type": "SECONDARY", "title": "Assessment of Acceptability of the Device", "description": "Percentage of subjects that overall found it very easy or fairly easy to use the inhaler, based on inhaler acceptability questionnaire", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "16 weeks", "groups": [{"id": "OG000", "title": "Dose 1 VR506 50 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "OG001", "title": "Dose 2 VR506 250 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}, {"id": "OG002", "title": "Dose 3 VR506 500 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "71"}, {"groupId": "OG002", "value": "63"}]}], "classes": [{"categories": [{"title": "Very easy", "measurements": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "38"}]}, {"title": "Fairly easy", "measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "21"}]}, {"title": "Missing", "measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "16 weeks", "eventGroups": [{"id": "EG000", "title": "Dose 1 VR506 50 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device", "deathsNumAffected": 0, "deathsNumAtRisk": 62, "seriousNumAffected": 0, "seriousNumAtRisk": 62, "otherNumAffected": 21, "otherNumAtRisk": 62}, {"id": "EG001", "title": "Dose 2 VR506 250 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device", "deathsNumAffected": 0, "deathsNumAtRisk": 71, "seriousNumAffected": 0, "seriousNumAtRisk": 71, "otherNumAffected": 33, "otherNumAtRisk": 71}, {"id": "EG002", "title": "Dose 3 VR506 500 mcg", "description": "VR506 inhalation powder delivered via a new dry powder inhaler device\n\nVR506: VR506 inhalation powder delivered via a new dry powder inhaler device", "deathsNumAffected": 0, "deathsNumAtRisk": 63, "seriousNumAffected": 0, "seriousNumAtRisk": 63, "otherNumAffected": 25, "otherNumAtRisk": 63}], "otherEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 12, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 35, "numAffected": 26, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 16, "numAffected": 12, "numAtRisk": 63}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 63}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 63}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 63}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Nasal Congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Painful Respiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Pharyngeal Erythema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Phyaryngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Cystisis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Ear Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Oropharyngitis Fungal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Otitis Media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Pharyngitis Streptococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Respiratory Tract Infection Viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Tonsillitis Streptococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Viral Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Vulvovaginal Candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Neuralgia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Radiculitis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Food Poisoning", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Pain in Extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Spinal Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Joint Sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Limb Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Tibia Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Alanine Aminotransferase Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Aspartate Aminotransferase", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Blood Pressure Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Cholecystitis Chronic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Eosinophilia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Middle Ear Effusion", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}, {"term": "Conjunctivitis", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 63}]}, {"term": "Tooth Extraction", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA (14.0)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 71}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 63}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Vectura's agreements with its investigators may vary. Publication may be delayed for Sponsor review and revisions/deletions can be required. Furthermore, a delay to publication may be required by the Sponsor in order to take steps to protect its proprietary information and/or intellectual property rights."}, "pointOfContact": {"title": "Gary Burgess, MD", "organization": "Vectura Limited", "email": "clinical.enquiries@vectura.com", "phone": "+44(0)1249 667700"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}